Short description
Ducentis is a pre-clinical stage company that aims to develop novel therapies for inflammation and autoimmune disease.
Description
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Witney, Oxfordshire, United Kingdom, Europe
Founded on
March 1, 2015
Exited on
September 8, 2022
Non-profit?
No
Acquired?
No
Employees count
1-10
Revenue range
$34056 - 789030
Sign in for full access
Investors
Cannot Access, Cannot Access
Sign in for full access
Founders
Philip Huxley, Rebecca Ashfield